Quick answer
Verify a blend component by component. The KLOW Stack page gives a total of 80 mg and a ≥98% HPLC specification but not the amount of each peptide, so a single purity percentage cannot tell you the ratio. Ask how purity is defined for the mixture, check that each of the four components is named on the lot certificate, and measure the ratio if an experiment depends on it. Supplied for laboratory research use only.
A four-peptide blend is harder to verify than any one of its components. A single-compound vial has one identity, one chromatogram and one mass. The KLOW Stack vial holds GHK-Cu, KPV, BPC-157 and TB-500 co-lyophilized together, and the product page gives a total of 80 mg per vial. This article is about what a laboratory should ask of the paperwork for a blend like that, why a single "≥98%" figure leaves questions open, and how to record the vial so that experiments stay comparable. It is written for laboratory research use only and makes no claim about effects of the blend.
If you want the biology of the individual peptides first, start with the KLOW Stack research overview and the KLOW peptide stack explained. This guide stays on analysis and documentation.
What the product page does and does not state
The page states that the vial is co-lyophilized, that the total peptide is 80 mg, that purity is specified at ≥98% by HPLC, and that component identity is reported on the batch certificate of analysis, and certificates for tested lots are published on the COA page. It does not state the milligram amount of each component; its per-component example (10 mg dissolved in 2 mL gives 5 mg/mL) is a worked illustration, not a composition. That gap is the single most important fact for anyone planning a quantitative experiment: with only a total, the concentration of any one peptide cannot be calculated from the label.
| Item | Stated on the product page | Left to the certificate or to you |
|---|---|---|
| Contents | GHK-Cu, KPV, BPC-157, TB-500 | Per-component identity result |
| Total peptide | 80 mg per vial | Peptide content versus salt and water |
| Purity | ≥98% by HPLC | How the figure is defined for a mixture |
| Form | Co-lyophilized powder, sealed clear glass vial | Appearance on receipt |
| Storage | 2–8 °C short term; −20 °C long term; protect from heat, moisture and light | Your own storage log |
| Component ratio | Not given | Ask for it, or measure it |
Because the ratio is not published on the page, regard any per-component concentration as unknown until the certificate or an assay says otherwise. Concentration of the whole vial is simple: total mass divided by diluent volume, c = m / V. The reconstitution calculator handles that part. Anything finer needs a number from a measurement.
Four molecules, four very different chromatographic behaviours
The four components differ enormously in size and polarity, which affects how any chromatogram of the mixture should look.
- GHK-Cu is the tripeptide Gly-His-Lys complexed with copper. The copper complex is the reason the cake and solution are blue. It is a small, polar, charged molecule that sits early in a reversed-phase run, and free copper and copper-bound forms can behave differently from the free tripeptide. The peptide is discussed as a modulator of multiple cellular pathways in skin regeneration (Pickart and colleagues, 2015); see also the GHK-Cu research overview.
- KPV is the tripeptide Lys-Pro-Val, the C-terminal tripeptide of α-melanocyte-stimulating hormone. It is also small and polar, and PepT1-mediated uptake of KPV into intestinal epithelial and immune cells was examined in a 2008 study (Dalmasso and colleagues, 2008).
- BPC-157 is a 15-residue peptide with a proline-rich core. It is the largest component, and has been reviewed as a musculoskeletal research peptide (Gwyer and colleagues, 2019).
- TB-500 is the acetylated heptapeptide fragment Ac-LKKTETQ from thymosin β4, which has been the subject of analytical method development in its own right (Ho and colleagues, 2012).
Two of these are tripeptides with very similar polarity, so on a generic gradient they may elute close together near the front of the run. A method that has not been shown to separate them cannot claim to have measured each one.
Why "≥98% purity" is ambiguous for a mixture
For a single peptide the statement means the main peak holds at least 98% of the integrated signal. For a blend, there are at least three possible readings:
- The four expected peaks together make up at least 98% of the integrated signal, with the remaining 2% being impurities of any kind.
- Each of the four peaks is individually at least 98% pure, measured on its own sample.
- The vial was assembled from four ingredient lots each specified at 98% or better, with no analysis of the final mixture.
All three are legitimate quality statements and they are not interchangeable. The first can still hide a badly skewed ratio; the third says nothing about the blend. A certificate that defines which reading applies is worth more than one that gives only the percentage. The page language, "identity confirmed on the batch COA", suggests asking directly.
A second subtlety is detector response. UV detection at 214 nm responds largely to peptide bonds, so a 15-residue peptide gives far more signal per mole than a tripeptide, and area percent is not the same as mass percent. A blend with 20 mg of a tripeptide and 20 mg of a 15-mer does not give equal peak areas. Area percent is a measure of signal, not of composition, and a ratio claim needs calibration with standards of each component.
The copper question
GHK binds copper(II), and the blend places that copper complex in the same vial as three other peptides. Copper can interact with histidine and other side chains, and its colour changes absorbance behaviour in the visible range. Whether copper alters any of the other three peptides over time is a question about the stability of the mixture rather than the components. The experimental questions are covered in does copper degrade other peptides in a blend; the point here is that a certificate generated at release does not answer it. An aged-vial re-analysis does.
A verification plan that scales with how much you depend on the vial
| Level | When it fits | What to do |
|---|---|---|
| 1. Record-keeping | Exploratory work where the blend is a qualitative probe | Log lot, appearance, storage, diluent, total concentration; confirm the lot string on the vial matches the published certificate |
| 2. Certificate review | Any publication-intended experiment | Read the method, chromatogram and component identity entries; ask how purity is defined for the mixture and whether the ratio is reported |
| 3. In-house check | Experiments in which the ratio matters | Run LC-MS on the reconstituted stock and confirm each expected mass; run the same method on single-component standards for retention time |
| 4. Quantitative assay | Experiments that attribute an effect to one component | Calibrate against standards for each peptide and report the measured amount of each, or use single-component vials instead |
The decision between a blend and separate vials is itself an experimental design question. A blend fixes the ratio; separate vials let you vary it and include single-component controls. The tradeoff is examined in peptide blends and research stacks.
Reading the lot certificate
- Lot string. It must equal the string on your vial, character for character.
- Test date. Record it beside your receipt date.
- Method. Look for column, gradient and wavelength. A purity figure with no method is only a statement.
- Chromatogram. Count the peaks and look at where the minor ones sit relative to the four main ones.
- Per-component identity. The page says identity of the blend components is reported on the batch certificate. Each of the four should be named.
- Counter-ion or content. If absent, the declared 80 mg is a mass of material, not necessarily of peptide base (Sikora and colleagues, 2020).
The certificate index is on the COA page, and the broader skill is explained in how to read a COA and KLOW Stack purity testing.
Handling facts from the product page
The page advises adding diluent slowly along the glass, swirling until clear, and not shaking or vortexing a four-component mixture; it also says to expect a blue cake and a blue solution because of the copper complex. Sealed vials are held at 2–8 °C short term and −20 °C long term, protected from heat, moisture and light, and solutions are refrigerated, protected from light and divided into portions to limit handling. Peptides in the dry state are generally much more stable than in solution (Manning and colleagues, 2010), so use of the whole vial in one preparation, rather than repeated opening, is the conservative approach. The step-by-step handling is in KLOW Stack reconstitution and storage.
What cannot be concluded from any of this
None of the references describes this commercial blend. The literature cited covers the individual peptides, analytical practice and salt forms. Nothing in it shows how the four peptides behave when combined in one vial over time, and no shelf life for a reconstituted four-component mixture has been published. Where your experiment needs that, measure it.
Related reading
- KLOW Stack research overview
- KLOW Stack purity testing
- KLOW Stack reconstitution and storage
- Where to buy KLOW Stack for research
- KLOW Stack product page
Frequently asked questions
How much of each peptide is in the KLOW Stack vial?
The product page gives only the total, 80 mg of blend per vial, and does not state the per-component amounts. Ask for the ratio on the certificate or measure it before attributing an effect to one component.
What does ≥98% HPLC purity mean for a blend?
It can mean the four expected peaks make up 98% of the signal, or that each component meets 98% on its own sample, or only that ingredient lots met a specification. A certificate that defines the reading removes the ambiguity.
Does HPLC peak area equal mass percent?
No. UV detection at 214 nm responds mainly to peptide bonds, so larger peptides give more signal per mole. Composition needs calibration with a standard of each component.
Why is the reconstituted solution blue?
The product page explains that the colour comes from the GHK-Cu copper complex, so a blue cake and blue solution are expected for this blend.
Can I calculate the concentration of BPC-157 in the vial from the label?
No, not from the label alone. The total concentration is mass divided by volume, but a single component needs its own stated or measured mass.
How is the KLOW Stack stored?
The product page lists 2–8 °C short term and −20 °C long term, protected from heat, moisture and light.
Why should a four-peptide mixture not be shaken?
The page advises adding diluent slowly along the glass and swirling until clear. Foam and shear are harder on peptide mixtures, and a blend gives you no single-component control for a damaged component.
Is there a published shelf life for a reconstituted blend?
No peer-reviewed shelf-life data for this four-component mixture were found. General peptide science says solution is far less stable than powder, so prepare what you need and record the date.
Where can I find a lot certificate?
The COA page lists published lot certificates, and the product page links to the lot document where one is available.
Is the KLOW Stack for use in people or animals?
No. It is supplied for laboratory research use only.
References
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043
- Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The role of counter-ions in peptides: an overview. Pharmaceuticals (Basel). 2020;13(12):442. doi:10.3390/ph13120442
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
